ZLOADR
Zloadr, the crypto publishing platform, has announced the release of a new technology known as DocTailor, which is tailored towards individuals and organisations seeking to produce legally binding smart contracts on the blockchain. This technology is designed to bridge the gap between non-crypto businesses and cryptocurrency holders.
With cryptocurrency heading towards a staggering a trillion in market cap, and predicted to climb further in the next few years, it’s an exciting time for crypto companies around the world. For Zloadr, a company that has already successfully established itself as a cornerstone for providing news to the crypto community, the release of this platform demonstrates a clear commitment to providing pioneering blockchain technologies to the African continent.
The DocTailor platform will be used solely to enable the creation of customisable legal smart contracts. Users of the platform will be able to select, find and replace clauses from standard legal document templates, from a database created by legal professionals. With these resources, users will be able to easily create and send tailor-made legal documents on the blockchain with the implementation of a smart contract.
Currently, creating unique legal smart contracts is time consuming and costly, particularly for users with no developer experience or little understanding of how to receive cryptocurrency, or properly utilise blockchain technology. Zloadr’s new platform will solve this problem by creating a whole new avenue for businesses that require legal contracts and agreements.
DocTailor will utilise Zloadr (ZDR) tokens, which are already on exchanges such as EtherDelta. ZDR tokens will be the sole designated means of payment on the platform, giving users access to DocTime where they can utilise features and clauses used in the creation of legal smart contracts.
"The platform will reinvent the current status quo in the legal industry, by effectively and securely bridging the gap between non-crypto businesses and an ever expanding crypto economy," says Sam Enrico Williams, Founder of Zloadr and DocTailor. "ZDR token holders will benefit from a 5% revenue distribution at the end of every quarter for holding onto their ZDR tokens too."
A list of the core features that will allow users to create contracts, and effectively grow revenues to their current non-crypto and crypto businesses, can be found on the current website of the platform, at doctailor.com .
About DocTailor
DocTailor is a unique customisable smart legal contract platform, which allows lawyers, individuals and organisations to send and create legal tailor-made smart contracts and agreements on the blockchain without developer experience.
About Zloadr
Zloadr is the first viral digital news publishing platform on the blockchain powered by influencers. Zloadr distributes content and grows income for content creators around the world.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180109005562/en/
Contact:
Media:
Zloadr Limited
Dominic
Brown, +44 7951 811 718
Chief Operation Officer
dominic@zloadr.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom